RT 100:新興醫藥品的考察、市場預測 (2030年)
RT 100 - Emerging Drug Insight and Market Forecast - 2030
|出版商||DelveInsight Business Research LLP||商品編碼||959700|
|出版日期||按訂單生產||內容資訊||英文 50 Pages
|RT 100:新興醫藥品的考察、市場預測 (2030年) RT 100 - Emerging Drug Insight and Market Forecast - 2030|
|出版日期: 按訂單生產||內容資訊: 英文 50 Pages||
本報告提供美國，歐洲5個國家(德國，法國，義大利，西班牙，英國)以及日本的7個主要市場上 RT-100 詳細說明 (含作用機制，劑量，合成途徑，法規的里程碑的研究開發活動，及其他的開發活動)，含SWOT分析，市場競爭企業，及其他新治療方法的未來市場評估。
"RT 100 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Heart failure in 7 Major Markets. A detailed picture of the RT 100 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
RT-100 is an investigational gene therapy product that is infused during cardiac catheterization - a commonly performed outpatient procedure similar to an angiography - directly into the arteries that feed the heart. This method of gene transfer has been shown to safely and efficiently deliver AC6 directly to heart muscle cells. The gene encoding human AC6 is delivered via a modified adenovirus vector that is able to enter the cells but cannot reproduce itself (Ad5.hAC6). The AC6 is taken in by the heart and has been shown to persist in heart muscle cells. Unlike small molecule drug treatments, which work to decrease demands on the body, this gene therapy is aimed at improving overall heart function. Rather than slow progression or minimize symptoms of CHF, RT-100 has the potential to halt and reverse the CHF-induced remodeling of the heart, enabling it to pump more effectively. Granted Fast Track designation by the U.S. Food and Drug Administration (FDA), RT-100 is in late-stage clinical development.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of RT 100 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of RT 100 covering trial interventions, trial conditions, trial status, start and completion dates.